Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Hold at Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on KNSA. Wall Street Zen raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Finally, Citigroup upped their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Stock Down 0.6%

Shares of KNSA opened at $53.34 on Monday. Kiniksa Pharmaceuticals International has a 52 week low of $25.70 and a 52 week high of $59.87. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 59.27 and a beta of 0.17. The stock’s 50-day moving average price is $48.98 and its 200-day moving average price is $44.61.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The company’s revenue was up 55.5% compared to the same quarter last year. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 483,654 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the completion of the transaction, the chief executive officer owned 431,904 shares of the company’s stock, valued at $22,398,541.44. This represents a 52.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. The trade was a 51.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 653,301 shares of company stock valued at $34,046,073. 51.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $31,000. KBC Group NV acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.